Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04628338
Other study ID # HCC 20-092
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date March 8, 2021
Est. completion date October 30, 2023

Study information

Verified date November 2023
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study proposes a safe dosing regimen IFN-γ that is sufficient to stimulate IFN-γ receptors on malignant blasts in patients who developed relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after alloSCT with no active or history of III-IV acute graft-versus-host disease (GVHD). It is hypothesized that IFN-γ will promote graft-vs-leukemia (GVL) in patients with AML/MDS that has relapsed after alloSCT.


Description:

Allogeneic hematopoietic stem cell transplantation (alloSCT) can cure patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, relapsed AML/MDS is the most significant single cause of treatment failure, and the majority of relapsed patients ultimately succumb. Alloreactive T cells in the donor graft can kill residual leukemia cells, mediating the graft-vs-leukemia (GVL) effect. Consistent with this, recipients of T cell-depleted grafts have higher rates of relapse. GVL is more potent against chronic leukemias than acute myeloblastic diseases, and the higher incidence of relapse in patients with AML/MDS reflects a failure in GVL. The central goal of this pilot trial will be to explore whether IFN-γ in this setting is safe and whether it has the desired biological activities on malignant blasts in vivo. IFN-γ will be tested in relapsed patients as monotherapy and in conjunction with donor leukocyte infusions (DLI). The clinical and biological information from this study is essential to design a phase II trial with a therapeutic endpoint. Treatment will be initiated at 100mcg (almost equal to the dose of 50 mcg/m2 for an adult) three times a week, with the potential to deescalate the frequency of injection for unacceptable toxicity. To explore whether this dosing regimen is sufficient to activate myeloblasts, pre- and post-treatment bone marrow specimens will be harvested to analyze for IFN-γ action (upregulation of HLA class I; HLA class II, ICAM-1 and phosphorylation of STAT1). The primary safety concern is the development of GVHD, which is routinely monitored for all alloSCT patients.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date October 30, 2023
Est. primary completion date October 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Recipients of allogeneic stem cell transplantation for acute myeloid leukemia or myelodysplastic syndrome from a human leukocyte antigen (HLA) matched donor - Relapsed of primary disease with 5% to 20% of blasts in the bone marrow by flow cytometry in the bone marrow with an clear leukemia-associated immunophenotype (If the patient received therapy to treat the relapse, he or she must have 5-20% residual blasts prior to enrollment on this study) - Performance status KPS score >60% (ECOG 0-2) - No increases in systemic immunosuppression in the prior four weeks other than to maintain therapeutic levels - No systemic corticosteroid with a dose higher than 0.5mg/kg/day prednisone or equivalent - No history of grade IV acute GVHD - No new systemic immunosuppressive medications in the prior two weeks initiated due to GVHD - Willingness to have bone marrow and peripheral blood collected as per the study protocol - Must be able to give informed consent - Age 18 or older Exclusion Criteria: - Contraindication to receive IFN-? including known hypersensitivity to interferon-gamma, E. coli derived products or any component of the product - Subjects with a positive pregnancy test or who are breastfeeding - For men or women of childing bearing potential (age < 50 without hysterectomy or oophorectomy or documented menopause), unwilling to use effective contraception for the duration of the study. - Primary engraftment failure - Active cardiac arrhythmias not controlled by medical management or current NYHA class II or higher congestive heart failure - Active ischemic heart disease not well controlled with medications - A seizure disorder not well controlled by medications - Estimated GFR <30 mL/min - AST/SGOT or ALT/SPOT > 5 x ULN - Total bilirubin > 3 x ULN - Chemotherapy (other than hypomethylating and/or venetoclax therapy) within the prior 4 weeks - Body surface area at or less than 1.5 m2, or greater than 2.5 m2 so as to minimize the variation in IFN-? exposure based on differences in BSA. - Patients less than 18 years old. - Pregnant or breastfeeding patients.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
IFN-? (interferon gamma-1b) injection
Dosage form: 100 mcg (2 million International Units) per 0.5 mL solution, administered subcutaneously Dose regimen: three times weekly (Weeks 0-7), once weekly (Weeks 8-12)

Locations

Country Name City State
United States UPMC Hillman Cancer Center Pittsburgh Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Sawa Ito, MD Horizon Pharma USA, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Upregulation HLA l (HLA-ABC) Upregulation of HLA l (HLA-ABC) in bone marrow malignant blasts post-IFN-? treatment, measured by the change in mean florescent intensity by flow cytometry. Up to 6 months
Primary Upregulation of HLA ll (HLA-DR/DQ) Upregulation of HLA ll (HLA-DR/DQ) in bone marrow malignant blasts post-IFN-? treatment, measured by the change in mean florescent intensity by flow cytometry. Up to 6 months
Primary Upregulation of ICAM-1 Upregulation of ICAM-1 in bone marrow malignant blasts post-IFN-? treatment, measured by the change in mean florescent intensity by flow cytometry as a percentage of positive cells. Up to 6 months
Primary Adverse events related to IFN-? Adverse events of IFN-? in relapsed patients after alloSCT per CTCAE v5.0. Up to 6 months
Primary Generation of phosphorylated-STAT1 Generation of phosphorylated-STAT1 in bone marrow malignant blasts post-IFN-? treatment, measured by the change in mean florescent intensity by flow cytometry as a percentage of positive cells. Up to 6 months
Secondary Malignant Blast Burden Change in malignant blasts number after IFN-? therapy and subsequent donor lymphocyte infusion. Up to 6 months
Secondary Incidence of GVHD Incidence of Graft Versus Host Disease (GVHD) progression or de novo GVHD after INF-g therapy and subsequent donor lymphocyte infusion. Up to 6 months
Secondary Incidence of de novo GVHD Incidence of graft-versus-host disease (GVHD) progression after IFN-? therapy and subsequent DLI. Up to 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Terminated NCT04313881 - Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) Phase 3
Recruiting NCT05088356 - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Phase 1
Recruiting NCT04003220 - Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Active, not recruiting NCT03755414 - Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation Phase 1
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Terminated NCT04866056 - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Phase 1/Phase 2
Recruiting NCT04701229 - Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes
Suspended NCT04485065 - Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS Phase 1
Recruiting NCT04174547 - An European Platform for Translational Research in Myelodysplastic Syndromes
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Completed NCT02508870 - A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes Phase 1
Completed NCT04543305 - A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies Phase 1
Recruiting NCT05384691 - Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions Phase 2
Recruiting NCT05365035 - A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts Phase 2
Recruiting NCT06008405 - Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy Phase 1
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Withdrawn NCT05170828 - Cryopreserved MMUD BM With PTCy for Hematologic Malignancies Phase 1